417P Comparative efficacy and safety of tislelizumab (TIS) vs other anti–PD-1 treatments in first-line (1L) gastric or gastroesophageal junction cancer (GC/GEJC): A network meta-analysis (NMA)
Year: 2025
Type: article
Study designs: Systematic Review, Meta-Analysis
Source: Annals of Oncology
Authors: M. Alsina Maqueda, J.A. Ajani, M. Moehler, K-W. Lee, W. Tang, J. Steenkamp, E. Prentiss, K. Wang, A. Bonner, L. Zhan
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Falk Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, World Health Organization, Gilead Sciences, FibroGen, Associazione Italiana di Oncologia Medica, Merck KGaA, Taiho Pharmaceutical, Exelixis, Jazz Pharmaceuticals, BeiGene, Fondazione Beretta, Advanced Accelerator Applications, Veracyte, Relay Therapeutics, MacroGenics, Seagen, Astellas Pharma, European Society for Medical Oncology, Servier, Ono Pharmaceutical, Ipsen, Scheme for Promotion of Academic and Research Collaboration, Daiichi Sankyo Europe
Award: G6396115521
OpenAlex ID: W4412480029